0JQ2.L
Kala Pharmaceuticals, Inc. [0JQ2.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
0JQ2.L Stock Summary
In the News
0JQ2.L Financial details
0JQ2.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 8.88 | 6.07 | 8.54 | 2.56 | |
| Net income per share | -124.73 | -137.89 | -99.59 | -108.32 | -29.48 | |
| Operating cash flow per share | -101.15 | -135.52 | -86.58 | -82.21 | -51.9 | |
| Free cash flow per share | -104.1 | -137.47 | -88.43 | -82.89 | -52.1 | |
| Cash per share | 319.39 | 125.91 | 147.15 | 70.68 | 46.42 | |
| Book value per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
| Tangible book value per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
| Share holders equity per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
| Interest debt per share | 131.24 | 104.04 | 68.96 | 59.95 | 24.95 | |
| Market cap | 115.84M | 364.33M | 360.36M | 79.12M | 28.37M | |
| Enterprise value | -55.05M | 278.88M | 283.09M | -13.01M | -42.13M | |
| P/E ratio | -1.74 | -3.86 | -3.45 | -0.55 | -0.63 | |
| Price to sales ratio | 0 | 59.98 | 56.64 | 7.04 | 7.29 | |
| POCF ratio | -2.14 | -3.93 | -3.97 | -0.73 | -0.36 | |
| PFCF ratio | -2.08 | -3.87 | -3.89 | -0.73 | -0.36 | |
| P/B Ratio | 1.1 | 12.27 | 3.6 | 4.71 | 1.5 | |
| PTB ratio | 1.1 | 12.27 | 3.6 | 4.71 | 1.5 | |
| EV to sales | 0 | 45.91 | 44.5 | -1.16 | -10.82 | |
| Enterprise value over EBITDA | 0.86 | -3.19 | -2.99 | 0.12 | 0.52 | |
| EV to operating cash flow | 1.02 | -3.01 | -3.12 | 0.12 | 0.53 | |
| EV to free cash flow | 0.99 | -2.97 | -3.06 | 0.12 | 0.53 | |
| Earnings yield | -0.58 | -0.26 | -0.29 | -1.8 | -1.58 | |
| Free cash flow yield | -0.48 | -0.26 | -0.26 | -1.38 | -2.79 | |
| Debt to equity | 0.67 | 2.4 | 0.72 | 4.7 | 2 | |
| Debt to assets | 0.32 | 0.46 | 0.33 | 0.57 | 0.44 | |
| Net debt to EBITDA | 2.65 | 0.98 | 0.81 | 0.85 | 0.87 | |
| Current ratio | 10.41 | 4.26 | 7.71 | 3.32 | 3.35 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.81 | 0.98 | 0.87 | 0.76 | 1.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 4.49 | 2.88 | 3.39 | 4.54 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0.01 | 0 | |
| Capex to revenue | 0 | -0.22 | -0.31 | -0.08 | -0.08 | |
| Capex to depreciation | -1.65 | -1.58 | -2.13 | -0.91 | -0.58 | |
| Stock based compensation to revenue | 0 | 1.64 | 2.09 | 1.43 | 1.8 | |
| Graham number | 742.01 | 366.94 | 462.49 | 176.38 | 90.98 | |
| ROIC | -0.37 | -0.87 | -0.56 | -1.14 | -1.43 | |
| Return on tangible assets | -0.3 | -0.61 | -0.47 | -1.02 | -0.52 | |
| Graham Net | 106.45 | -40.17 | 40.43 | -10.44 | 1.89 | |
| Working capital | 160.02M | 80.71M | 149.15M | 86.94M | 60.26M | |
| Tangible asset value | 104.98M | 29.69M | 100M | 16.8M | 18.97M | |
| Net current asset value | 61.04M | -19.15M | 49.77M | 1.74M | 18.1M | |
| Invested capital | 0.67 | 2.4 | 0.72 | 4.7 | 2 | |
| Average receivables | 1 | 5.78M | 10.58M | 12.47M | 7.77M | |
| Average payables | 3.32M | 3.98M | 2.12M | 3.31M | 3.87M | |
| Average inventory | 2.05M | 4.37M | 4.94M | 6.93M | 4.32M | |
| Days sales outstanding | 0 | 694.85 | 551 | 498.3 | 18.29 | |
| Days payables outstanding | 0 | 457.7 | 235.41 | 436.45 | 403.78 | |
| Days of inventory on hand | 0 | 844.88 | 714.02 | 769.64 | 0 | |
| Receivables turnover | 0 | 0.53 | 0.66 | 0.73 | 19.96 | |
| Payables turnover | 0 | 0.8 | 1.55 | 0.84 | 0.9 | |
| Inventory turnover | 0 | 0.43 | 0.51 | 0.47 | 2.56M | |
| ROE | -0.64 | -3.18 | -1.04 | -8.49 | -2.36 | |
| Capex per share | -2.95 | -1.95 | -1.85 | -0.67 | -0.21 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.28 | 0 | 0 | 0 | 0 | |
| Net income per share | 19.25 | -7.97 | -6.99 | -4.36 | -3.41 | |
| Operating cash flow per share | -10.37 | -8.53 | -4.68 | -3.18 | -1.16 | |
| Free cash flow per share | -10.4 | -8.54 | -4.74 | -3.27 | -1.27 | |
| Cash per share | 34.79 | 43.82 | 30.77 | 24.78 | 21.98 | |
| Book value per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
| Tangible book value per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
| Share holders equity per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
| Interest debt per share | 28.23 | 23.55 | 16.09 | 14.06 | 13.28 | |
| Market cap | 17.03M | 30.05M | 30.35M | 34.38M | 22.54M | |
| Enterprise value | -35.36M | -40.44M | -33.28M | -14.87M | -33.52M | |
| P/E ratio | 0.15 | -0.58 | -0.52 | -0.83 | -0.65 | |
| Price to sales ratio | 40.54 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.09 | -2.19 | -3.13 | -4.53 | -7.64 | |
| PFCF ratio | -1.08 | -2.18 | -3.1 | -4.4 | -6.97 | |
| P/B Ratio | -17.59 | 1.58 | 1.29 | 1.97 | 2.01 | |
| PTB ratio | -17.59 | 1.58 | 1.29 | 1.97 | 2.01 | |
| EV to sales | -84.2 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 2.46 | 4.46 | 3.33 | 1.62 | 3.21 | |
| EV to operating cash flow | 2.26 | 2.94 | 3.44 | 1.96 | 11.35 | |
| EV to free cash flow | 2.25 | 2.94 | 3.4 | 1.9 | 10.37 | |
| Earnings yield | 1.71 | -0.43 | -0.48 | -0.3 | -0.39 | |
| Free cash flow yield | -0.92 | -0.46 | -0.32 | -0.23 | -0.14 | |
| Debt to equity | -44.05 | 2 | 1.42 | 1.92 | 3.02 | |
| Debt to assets | 0.5 | 0.44 | 0.46 | 0.5 | 0.55 | |
| Net debt to EBITDA | 3.64 | 7.77 | 6.37 | 5.38 | 5.38 | |
| Current ratio | 2.1 | 3.35 | 6.95 | 6.65 | 5.62 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | -0.54 | 1.07 | 0.67 | 0.73 | 0.34 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 12.84 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0.03 | 0.1 | |
| Capex to revenue | -0.09 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.25 | -0.28 | -1.4 | -2.78 | -3.56 | |
| Stock based compensation to revenue | 3.16 | 0 | 0 | 0 | 0 | |
| Graham number | 16.66 | 45.97 | 42.24 | 26.81 | 18.38 | |
| ROIC | -0.35 | -0.16 | -0.18 | -0.18 | -0.23 | |
| Return on tangible assets | 0.34 | -0.15 | -0.2 | -0.16 | -0.14 | |
| Graham Net | -22.5 | 1.78 | 7.23 | 4.3 | 2.45 | |
| Working capital | 44.43M | 60.26M | 61.08M | 55.68M | 47.6M | |
| Tangible asset value | -968K | 18.97M | 23.46M | 17.49M | 11.22M | |
| Net current asset value | -1.99M | 18.1M | 22.58M | 16.53M | 8.01M | |
| Invested capital | -44.05 | 2 | 1.42 | 1.92 | 3.02 | |
| Average receivables | 7.01M | 192.5K | 155K | 116K | 117K | |
| Average payables | 8.95M | 5.09M | 1.91M | 878.5K | 773.5K | |
| Average inventory | 12.5K | 1 | 1 | 1 | 1 | |
| Days sales outstanding | 40.71 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 60.12K | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0.01 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 2.21 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 11K | 0 | 0 | 0 | 0 | |
| ROE | -30.03 | -0.68 | -0.62 | -0.6 | -0.78 | |
| Capex per share | -0.03 | -0.01 | -0.05 | -0.09 | -0.11 |
0JQ2.L Frequently Asked Questions
What is Kala Pharmaceuticals, Inc. stock symbol ?
Kala Pharmaceuticals, Inc. is a US stock , located in Arlington of Ma and trading under the symbol 0JQ2.L
What is Kala Pharmaceuticals, Inc. stock quote today ?
Kala Pharmaceuticals, Inc. stock price is $7.37 today.
Is Kala Pharmaceuticals, Inc. stock public?
Yes, Kala Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 257
- Market Capitalization 20.36M
- Employee 34
- CEO Mr. Mark T. Iwicki
- Headquarters Arlington,MA,US
- IPO Date 2018-01-29
-
Website
https://www.kalarx.com 
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
